Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study probes how COVID shots alter immune cell activity

NCT ID NCT05655351

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed early-phase study looked at how mRNA COVID-19 vaccines (Pfizer or Moderna) affect certain immune cells called monocytes in people of different ages. Researchers measured changes in reactive oxygen species (a type of cell activity) and a blood protein called AngII before and after vaccination. The study included 30 healthy adults split into three age groups: under 30, 30-60, and over 60. The goal was to understand the vaccine's biological effects, not to test its safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mRNA COVID-19 vaccine (Pfizer or Moderna)
What this could lead to
If successful, this could help explain how the vaccine affects immune cells and why responses vary by age.
What could go wrong
This is a very small, early-stage study with only 30 participants. It measures lab markers, not health outcomes, so results may not lead to direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

30 people

The number who actually took part.

Started

Dec 2022

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Candidate for SARS-CoV-2 vaccination with an mRNA vaccine (Pfizer, Moderna). * Subject has given free and informed consent. * Subject who has signed the consent form. * Person affiliated to or beneficiary of a health insurance plan. Exclusion Criteria: * Patients under treatment with N-acetylcysteine or sartan. * Patients with a dysimmune pathology or immunosuppressive treatment. * Person infected with SARS-CoV-2 within 3 months prior to inclusion. * Person participating in a category 1 defined RIPH. * Subject in an exclusion period as determined by another study. * Person under court protection, guardianship or trusteeship. * Subject who is unable to give consent. * Subject for whom it is impossible to give clear information. * Pregnant or breastfeeding woman.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronavirus infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease Coronaviridae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronavirus infections

Contacts and locations

Locations

  • CHU de Nîmes, Hôpital Universitaire Caremeau

    Nîmes, France, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.